GammaCan, Life Therapeutics to develop anticancer therapy drug

By Elaine Rigoli

Tampa, Fla., June 21 - After receiving a $1 million grant, GammaCan International and Life Therapeutics said they will develop VitiGam, an anticancer product designed to target metastatic malignant melanoma patients with stage 3 and stage 4 disease.

VitiGam, an intravenous IgG-based product and anticancer immunotherapy, is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population.

GammaCan said its scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in-vitro and mouse xenograft melanoma models.

Thus, GammaCan said it expects VitiGam to provide anti-melanoma activity directed specifically against malignant melanoma cells and non-specific anticancer activity - as is the case with IgG in general.

GammaCan is a biopharmaceutical company located in Givat Shmuel, Israel.

Life Therapeutics is an international company that specializes in niche therapeutic hyperimmune products and is based in Atlanta.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.